Suppliers and packagers for generic pharmaceutical drug: CASPOFUNGIN ACETATE

CASPOFUNGIN ACETATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227	NDA	Merck Sharp & Dohme LLC	0006-3822-10	1 VIAL, SINGLE-USE in 1 CARTON (0006-3822-10) / 10.8 mL in 1 VIAL, SINGLE-USE	2001-01-26
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227	NDA	Merck Sharp & Dohme LLC	0006-3823-10	1 VIAL, SINGLE-USE in 1 CARTON (0006-3823-10) / 10.8 mL in 1 VIAL, SINGLE-USE	2001-01-26
Fresenius Kabi Usa	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	206110	NDA	Fresenius Kabi USA, LLC	63323-356-10	10 VIAL, SINGLE-DOSE in 1 CARTON (63323-356-10) / 10.8 mL in 1 VIAL, SINGLE-DOSE (63323-356-01)	2016-12-30

Caspofungin Acetate Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the supply landscape for caspofungin acetate, an echinocandin antifungal medication. Key suppliers and manufacturing capabilities are identified, along with patent expiration timelines impacting market entry for generics.

What is Caspofungin Acetate?

Caspofungin acetate is an antifungal drug belonging to the echinocandin class. It functions by inhibiting the synthesis of beta-(1,3)-D-glucan, a vital component of fungal cell walls. This inhibition disrupts the integrity of the cell wall, leading to fungal cell lysis and death. Caspofungin is administered intravenously and is indicated for treating serious fungal infections caused by Candida species, including invasive candidiasis, and for empirical treatment of suspected fungal infections in febrile neutropenic patients. It is also used to treat esophageal candidiasis and as an adjunct therapy for invasive aspergillosis in patients refractory to other treatments.

The chemical structure of caspofungin acetate is characterized by a cyclic hexapeptide backbone with a lipid side chain. Its molecular formula is C52H85N7O15 and its molecular weight is approximately 1044.27 g/mol. The drug is formulated as a sterile powder for reconstitution for intravenous infusion.

Who are the Key Suppliers of Caspofugin Acetate?

The supply chain for caspofungin acetate involves both the active pharmaceutical ingredient (API) manufacturers and the finished drug product manufacturers. Several companies globally have demonstrated capabilities in producing this complex molecule.

Active Pharmaceutical Ingredient (API) Manufacturers

API production requires specialized fermentation and synthetic chemistry expertise due to the complex, semi-synthetic nature of echinocandins.

• Merck & Co., Inc. (as the originator of Cancidas®): Merck developed and markets the branded caspofungin acetate under the name Cancidas®. While Merck manufactures the API for its branded product, it may also engage contract manufacturing organizations (CMOs) or sell the API to other entities. Information on Merck's specific API production sites for caspofungin is proprietary.
• Contract Manufacturing Organizations (CMOs) and Generic API Producers: A significant portion of the API supply is expected to come from CMOs and dedicated generic API manufacturers. These companies often possess the necessary expertise in fermentation and downstream processing for complex APIs. Examples of companies known for their broad API portfolios, which may include complex antifungals, include:
  • Nanjing Pharma-tech Co., Ltd.: A China-based pharmaceutical ingredient supplier.
  • Synthon International: A global developer and manufacturer of generic medicines, often involved in API sourcing and production.
  • Hetero Drugs Ltd.: A leading Indian pharmaceutical company with extensive API manufacturing capabilities.
  • Lupin Ltd.: An Indian multinational pharmaceutical company that manufactures and markets a wide range of branded and generic formulations, including APIs.
  • Cipla Ltd.: Another major Indian pharmaceutical company with substantial API manufacturing operations.
  • Zydus Lifesciences (formerly Cadila Healthcare): An Indian pharmaceutical company with integrated API and finished dosage form manufacturing.

The specific manufacturing locations for these companies are often distributed across India, China, and Europe, with facilities adhering to stringent GMP (Good Manufacturing Practice) standards.

Finished Drug Product Manufacturers

Finished drug product manufacturing involves formulating the API into the final sterile powder for injection, including lyophilization and aseptic filling.

• Merck & Co., Inc.: Produces the branded Cancidas® at its manufacturing facilities.
• Generic Pharmaceutical Companies: Numerous generic manufacturers are entering or have entered the market with their own caspofungin acetate formulations. These companies rely on sourcing API from third-party manufacturers or producing it in-house. Key generic players with a presence in injectable generics include:
  • Teva Pharmaceutical Industries Ltd.: A major global generic drug manufacturer.
  • Viatris Inc.: Formed by the merger of Mylan and Pfizer's Upjohn, Viatris has a broad portfolio of injectable generics.
  • Fresenius Kabi: A global healthcare company specializing in infusion therapies, including generic injectable medicines.
  • Hikma Pharmaceuticals PLC: A multinational pharmaceutical group that develops, manufactures, and markets a broad range of generic and branded products, with a strong focus on injectables.
  • Fresenius SE & Co. KGaA: Parent company of Fresenius Kabi, with broad pharmaceutical manufacturing interests.
  • Accord Healthcare (Intas Pharmaceuticals): A significant global pharmaceutical manufacturer with a presence in sterile injectables.
  • Amneal Pharmaceuticals: A US-based pharmaceutical company that manufactures and markets generic and specialty products.

The manufacturing sites for finished drug products are typically located in regions with robust pharmaceutical manufacturing infrastructure, including the United States, Europe, India, and China. These facilities undergo regular inspections by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

What are the Patent Expirations and Market Entry Implications?

The patent landscape for caspofungin acetate has significantly influenced market dynamics, particularly concerning generic competition. The primary patent for caspofungin, held by Merck, has expired, opening the door for generic manufacturers.

Key Patent Expirations

• US Patent 5,378,729: This foundational patent, covering caspofungin and its methods of use, expired in 2011.
• US Patent 6,541,594: This patent, relating to specific crystalline forms of caspofungin mesylate, expired in 2018.
• US Patent 7,132,530: This patent, covering pharmaceutical compositions and methods of use for caspofungin, expired in 2019.
• US Patent 7,807,650: This patent, relating to methods of treating fungal infections with caspofungin, expired in 2023.

The expiration of these core patents, particularly the method of use patents, has facilitated the market entry of generic caspofungin acetate products. The initial exclusivity period for the branded drug has concluded, leading to increased competition.

Generic Market Entry and Competition

The expiration of key patents has led to the introduction of multiple generic versions of caspofungin acetate. This has resulted in:

• Price Reductions: Increased competition from generic manufacturers has driven down the price of caspofungin acetate, making the treatment more accessible.
• Increased Market Share for Generics: Generic products now hold a substantial share of the caspofungin acetate market.
• Supply Chain Diversification: The demand for generic caspofungin has spurred the growth and diversification of API and finished product manufacturers.
• Regulatory Approvals: Regulatory agencies like the FDA have approved Abbreviated New Drug Applications (ANDAs) for generic caspofungin acetate, allowing these products to be marketed in the United States. For example, the FDA has approved ANDAs from companies including Teva Pharmaceuticals, Fresenius Kabi, and Mylan (now part of Viatris).

The ongoing availability of caspofungin acetate from multiple suppliers, supported by expired patents, ensures a competitive market with a diversified supply chain for this critical antifungal.

Manufacturing Challenges and Regulatory Considerations

The production of caspofungin acetate presents specific manufacturing challenges and requires adherence to strict regulatory standards.

Manufacturing Complexity

• Fermentation and Semi-Synthesis: Caspofungin is produced through a combination of fermentation (to obtain a precursor molecule) and subsequent chemical synthesis. This dual approach requires specialized bioreactors, fermentation expertise, and sophisticated synthetic chemistry capabilities. Controlling fermentation parameters to ensure consistent precursor quality is critical.
• Chirality and Stereochemistry: The molecule contains multiple chiral centers, demanding precise control over stereochemistry during synthesis to produce the correct isomer and avoid impurities.
• Purification: Achieving high purity levels (typically >99%) for an injectable API is essential. This involves multi-step purification processes such as chromatography and crystallization, which can be complex and costly.
• Sterile Manufacturing: The final drug product must be manufactured under sterile conditions, typically involving aseptic processing and lyophilization (freeze-drying). This requires highly controlled environments (e.g., ISO 5 cleanrooms), specialized equipment, and rigorous validation protocols to prevent microbial contamination.
• Stability: Ensuring the stability of the lyophilized product and its reconstituted solution is crucial for efficacy and safety. Excipients and formulation parameters are optimized to achieve desired shelf life.

Regulatory Compliance

• Good Manufacturing Practices (GMP): All manufacturing facilities, whether for API or finished product, must comply with current Good Manufacturing Practices (cGMP) as defined by regulatory bodies like the FDA, EMA, and other national health authorities. This includes stringent controls over quality systems, facility design, equipment, personnel, materials, and processes.
• Drug Master Files (DMFs): API manufacturers typically file Drug Master Files (DMFs) with regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, and quality control of the API, which are reviewed by regulatory authorities in conjunction with a finished drug product application.
• ANDA Submissions: Generic drug manufacturers submit Abbreviated New Drug Applications (ANDAs) to the FDA, demonstrating that their product is bioequivalent to the reference listed drug (RLD) and that their manufacturing process meets all regulatory requirements.
• Inspections and Audits: Manufacturing sites are subject to routine inspections by regulatory agencies and audits by their customers (finished product manufacturers) to ensure ongoing compliance.
• Impurity Profiling: Regulatory authorities require thorough characterization and control of all impurities present in the API and finished drug product, including process-related impurities and degradation products. This often involves detailed analytical method development and validation.

The complexity of caspofungin acetate manufacturing means that only a limited number of specialized API producers and CMOs can effectively produce it at commercial scale. However, the demand created by patent expirations has fostered investment and development in this area among established generic players and specialized contract manufacturers.

Key Takeaways

• Caspofungin acetate is an essential echinocandin antifungal for serious fungal infections.
• The supply chain comprises API manufacturers and finished drug product manufacturers, with significant global players in India, China, Europe, and North America.
• Key API suppliers include Merck (originator) and a growing number of generic API producers and CMOs such as Nanjing Pharma-tech, Synthon, Hetero Drugs, Lupin, Cipla, and Zydus Lifesciences.
• Leading generic finished product manufacturers include Teva, Viatris, Fresenius Kabi, Hikma, and Accord Healthcare.
• The expiration of primary patents, most notably US Patent 5,378,729 in 2011, has paved the way for generic market entry. Subsequent patent expirations in 2018, 2019, and 2023 have further solidified generic competition.
• Generic market entry has led to price reductions and a diversified supply chain for caspofungin acetate.
• Manufacturing caspofungin acetate is complex, involving fermentation, semi-synthesis, stringent purification, and sterile processing, necessitating adherence to cGMP regulations and robust quality control.

FAQs

1. Which companies hold the primary patents for caspofungin acetate? Merck & Co., Inc. held the primary patents for caspofungin acetate, including foundational patents related to the molecule and its use. These patents have now expired.

2. What is the typical lead time for sourcing caspofungin acetate API from a new supplier? The lead time for sourcing caspofungin acetate API from a new supplier can range from 6 to 18 months. This includes supplier qualification, analytical method transfer, process validation, and regulatory filing support (e.g., DMF updates).

3. Are there any specific regulatory hurdles unique to caspofungin acetate API manufacturing? The primary regulatory hurdles involve demonstrating consistent control over the complex fermentation process, managing stereoisomeric purity, and achieving the high purity standards required for injectable APIs, all under strict cGMP compliance.

4. What is the estimated market size for generic caspofungin acetate in the United States? While precise real-time market size figures fluctuate, the U.S. market for caspofungin acetate injectables, encompassing both branded and generic, has historically been in the hundreds of millions of dollars annually, with generic penetration significantly impacting revenue.

5. Can caspofungin acetate API be manufactured at facilities that produce other echinocandins? Yes, facilities with expertise in fermentation and complex semi-synthesis, and that are equipped to handle antifungal APIs, can often manufacture caspofungin acetate. However, dedicated lines or strict cleaning validation protocols are essential to prevent cross-contamination, especially with other potent APIs.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/

[2] United States Patent and Trademark Office. (n.d.). USPTO Patent Search. Retrieved from https://patft.uspto.gov/

[3] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from https://www.ema.europa.eu/en/medicines

[4] Various company press releases and investor reports from Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., Fresenius Kabi, and other listed pharmaceutical companies. (Specific dates and titles vary based on reporting cycles).